Genetics
CETP genetic variants predict baseline LDL cholesterol but not atorvastatin response in Jordanian patients (Drug Metab Pers Ther 2022)
Original title: No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients
In one hundred and fifty hyperlipidaemic patients from the University of Jordan Hospital treated with 20 mg atorvastatin, researchers genotyped LDLR AvaII and CETP TaqIb and rs1532624 variants using PCR-RFLP and Sanger sequencing to assess their influence on atorvastatin efficacy. All three variants, including both CETP variants, showed a significant association with baseline LDL cholesterol levels at diagnosis (P less than 0.05). However, none of the tested variants, including the CETP variants, showed a significant association with the degree of LDL cholesterol reduction after atorvastatin therapy (P greater than 0.05), indicating that while CETP genotype shapes baseline LDL cholesterol in this Jordanian population, it does not predict how well patients respond to atorvastatin.
Original abstract
Objectives: Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (CETP) and LDL receptor (LDLR) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR AvaII, CETP TaqIb, and Rs1532624 on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.
Methods: One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of LDLR AvaII and CETP TaqIb genetic variants. The genotyping of CETP Rs1532624 variant was done by Sanger DNA-Sequencing.
Results: LDLR AvaII and CETP TaqIb and Rs1532624 variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.
Conclusions: Results demonstrated a significant association between the LDLR AvaII and CETP TaqIb, and Rs1532624 genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.